Biogen Inc. $BIIB Stock Holdings Lifted by QRG Capital Management Inc.

QRG Capital Management Inc. lifted its position in Biogen Inc. (NASDAQ:BIIB) by 769.6% in the 1st quarter, HoldingsChannel reports. The institutional investor owned 33,002 shares of the biotechnology company’s stock after buying an additional 29,207 shares during the quarter. QRG Capital Management Inc.’s holdings in Biogen were worth $6,050,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in BIIB. Rothschild Investment LLC grew its position in Biogen by 12.3% in the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after acquiring an additional 56 shares in the last quarter. Itau Unibanco Holding S.A. raised its holdings in shares of Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 66 shares in the last quarter. Advisory Services Network LLC lifted its stake in shares of Biogen by 3.9% in the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after purchasing an additional 68 shares during the last quarter. Davis Investment Partners LLC lifted its stake in shares of Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after purchasing an additional 71 shares during the last quarter. Finally, Optas LLC boosted its holdings in Biogen by 4.5% in the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 73 shares in the last quarter. Institutional investors and hedge funds own 87.93% of the company’s stock.

Analyst Ratings Changes

BIIB has been the topic of a number of analyst reports. Cantor Fitzgerald reissued an “overweight” rating on shares of Biogen in a report on Monday, June 22nd. Rothschild & Co Redburn boosted their target price on Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. Canaccord Genuity Group upped their target price on Biogen from $230.00 to $245.00 and gave the stock a “buy” rating in a research report on Wednesday, April 1st. Truist Financial lowered their price target on Biogen from $193.00 to $189.00 and set a “hold” rating on the stock in a report on Monday, April 13th. Finally, The Goldman Sachs Group increased their price target on Biogen from $231.00 to $238.00 and gave the company a “buy” rating in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $217.41.

Biogen Price Performance

BIIB stock opened at $216.12 on Monday. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $219.72. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The company has a market cap of $31.91 billion, a PE ratio of 23.19 and a beta of 0.16. The business’s 50-day simple moving average is $196.61 and its 200 day simple moving average is $187.11.

Biogen (NASDAQ:BIIB) last issued its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The business had revenue of $2.48 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the prior year, the company posted $3.02 earnings per share. Biogen’s revenue was up 1.9% on a year-over-year basis. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts anticipate that Biogen Inc. will post 13.95 earnings per share for the current year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.